This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell International Inc. (HON) and American Tower Corporation (AMT).
NOCNegative Net Change AMTPositive Net Change HONNegative Net Change NVOPositive Net Change APHPositive Net Change VMCPositive Net Change
multi-sector-conglomerates pharmaceuticals reit
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change KRYSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
BAYRYPositive Net Change BEAMPositive Net Change ZTSNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
by Zacks Equity Research
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific
by Zacks Equity Research
GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.
ABTNegative Net Change BSXNegative Net Change JNJNegative Net Change GEHCNegative Net Change
medical pharmaceuticals
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
by Kinjel Shah
Both JNJ and ABBV expect their sales and profits to improve in 2025.
JNJNegative Net Change ABBVNegative Net Change
pharmaceuticals
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
by Ahan Chakraborty
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
NVOPositive Net Change PCRXPositive Net Change RARENegative Net Change ACADPositive Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Wide-Moat Stocks to Invest in for Long-Term Growth
by Anindya Barman
Investing in wide-moat stocks like PFE, ASML, LRCX and KO can be a strategy for long-term wealth creation due to their ability to deliver consistent returns.
INTCPositive Net Change KONegative Net Change PFENegative Net Change ASMLNegative Net Change LRCXPositive Net Change PEPNegative Net Change TSMPositive Net Change
consumer-staples electronics pharmaceuticals semiconductor thematic
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
PFENegative Net Change NVOPositive Net Change LLYNegative Net Change
pharmaceuticals
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth
by Zacks Equity Research
AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.
RHHBYNegative Net Change JNJNegative Net Change AMGNNegative Net Change
pharmaceuticals
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.
SNYNegative Net Change NVAXNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
BioMarin's First-Quarter Earnings & Sales Beat Estimates
by Zacks Equity Research
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
SNYNegative Net Change BMRNNegative Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs earnings medical pharmaceuticals
Viatris Q1 Earnings Release: What's in Store for the Stock?
by Zacks Equity Research
VTRS' Q1 results are likely to gain from new product launches in all major geographies.
VRTXNegative Net Change ANIPNegative Net Change DNLINegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
TEVANegative Net Change BEAMPositive Net Change FOLDNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
by Zacks Equity Research
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change BPMCNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
by Zacks Equity Research
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
REGNNegative Net Change ALNYNegative Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
PFENegative Net Change MRKNegative Net Change SMMTNegative Net Change
biotechs earnings medical pharmaceuticals
Zacks.com featured highlights Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont
by Zacks Equity Research
Fox, Universal Technical Institute, Pfizer, Tenet Healthcare and Newmont have been highlighted in this Screen of The Week article.
PFENegative Net Change THCNegative Net Change NEMPositive Net Change UTIPositive Net Change FOXANegative Net Change
pharmaceuticals
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
by Zacks Equity Research
AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.
AZNPositive Net Change JNJNegative Net Change AMGNNegative Net Change
pharmaceuticals
Company News for May 2, 2025
by Zacks Equity Research
Companies In The News Are: CVS, LLY, CAH, ICE.
ICEPositive Net Change LLYNegative Net Change CAHPositive Net Change CVSNegative Net Change
finance medical pharmaceuticals
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
by Ekta Bagri
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
by Zacks Equity Research
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.
PFENegative Net Change NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
by Zacks Equity Research
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Initial Claims More Than Expectations
by Zacks Equity Research
Initial Claims More Than Expectations.
AMZNPositive Net Change AAPLPositive Net Change MAPositive Net Change LLYNegative Net Change AMGNNegative Net Change MCDPositive Net Change CVSNegative Net Change WNegative Net Change TWLOPositive Net Change
medical pharmaceuticals restaurants